Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction.
Measurements of haemostatic function and metabolic and angiographic indices of risk were included in a prospective cohort study of variables predictive of recurrences within 3 years in 109 unselected men with a first myocardial infarction (MI) before the age of 45. In the course of follow-up, 16 patients had at least one reinfarction (fatal recurrences in 9 and nonfatal in 7) and 1 died suddenly. High plasma concentrations of the fast-acting plasminogen activator inhibitor were independently related to reinfarction along with dyslipoproteinaemia involving VLDL and HDL, poor left ventricular performance, and multiple-vessel coronary artery disease. Besides being independently associated with reinfarction in the present population, high triglyceride levels were possibly connected with a predisposition to thrombosis through a coexisting high level of plasminogen activator inhibitor. The data indicate that reduced fibrinolytic capacity due to increased plasma levels of the plasminogen activator inhibitor predisposes to reinfarction in a complex interplay with atherogenic factors, multiple coronary lesions, and compromised left ventricular function.
D000328:Adult; D005340:Fibrinogen / Q000032:analysis; D005500:Follow-Up Studies; D006023:Glycoproteins / Q000097:blood*; D006487:Hemostasis; D006801:Humans; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008722:Methods; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood*; D010960:Plasminogen Activators / Q000037:antagonists & inhibitors*; D015849:Plasminogen Inactivators; D011446:Prospective Studies; D012008:Recurrence; D012306:Risk; D014280:Triglycerides / Q000097:blood
D006023:Glycoproteins; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D015849:Plasminogen Inactivators; D014280:Triglycerides; D005340:Fibrinogen; D010960:Plasminogen Activators